Mizolastine | CAS#108612-45-9 | antihistamine

MedKoo Cat#: 584735 | Name: Mizolastine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mizolastine is a selective histamine H1 receptor antagonist.

Chemical Structure

Mizolastine

CAS#108612-45-9

Theoretical Analysis

MedKoo Cat#: 584735

Name: Mizolastine

CAS#: 108612-45-9

Chemical Formula: C24H25FN6O

Exact Mass: 432.2074

Molecular Weight: 432.50

Elemental Analysis: C, 66.65; H, 5.83; F, 4.39; N, 19.43; O, 3.70

Price and Availability

Size	Price	Availability	Quantity
1g	USD 350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Mizollen; SL 85.0324; Mistalin; Mistamine; Mizolastina; Mizolastine

IUPAC/Chemical Name

2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone

InChi Key

PVLJETXTTWAYEW-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)

SMILES Code

O=C1NC(N(C2CCN(C3=NC4=CC=CC=C4N3CC5=CC=C(F)C=C5)CC2)C)=NC=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Mizolastine is a histamine H1 receptor antagonist (second generation antihistamine).

In vitro activity:

This study investigated the influence of MIZ (mizolastine) on proangiogenesis factors, vascular endothelial cell growth factor (VEGF), tumour necrosis factor (TNF)-alpha and keratinocyte-derived chemokine (KC) in murine mast cells by using ELISA and RT-PCR, as compared with dexamethasone (DEX) and loratadine (LOR). These results show that MIZ is effective in the inhibition of KC, VEGF and TNF-alpha release induced by an IgE-dependent mechanism, in a time- and dose-dependent manner. Reference: Clin Exp Dermatol. 2005 Mar;30(2):165-70. https://pubmed.ncbi.nlm.nih.gov/15725247/

In vivo activity:

In the current study, the capacity of YNB (Yunnan Baiyao) to ameliorate inflammation was compared in carrageenan‑induced and AA‑induced acute inflammation of the rat paw with celecoxib and mizolastine, respectively (n=24 per group). Celecoxib ameliorated carrageenan‑induced paw edema, and mizolastine ameliorated AA‑induced rat paw edema. Reference: Mol Med Rep. 2017 Oct;16(4):4045-4053. https://pubmed.ncbi.nlm.nih.gov/28765972/

	Solvent	mg/mL	mM
Solubility
	DMSO	25.0	57.80
	Chloroform	10.0	23.12
	Water	1.0	2.31

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 432.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Yan Y, Wang B, Zuo YG, Qu T. Inhibitory effects of mizolastine on ultraviolet B-induced leukotriene B4 production and 5-lipoxygenase expression in normal human dermal fibroblasts in vitro. Photochem Photobiol. 2006 May-Jun;82(3):665-9. doi: 10.1562/2005-08-17-RA-652. PMID: 16402861. 2. Xia Q, Yang S, Zhang SQ, Chen B, Wang DB, Zhu QX, Wang Y, Yan KL, He PP, Zhang XJ. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol. 2005 Mar;30(2):165-70. doi: 10.1111/j.1365-2230.2005.01721.x. PMID: 15725247. 3. Ren X, Zhang M, Chen L, Zhang W, Huang Y, Luo H, Li L, He H. The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model. Mol Med Rep. 2017 Oct;16(4):4045-4053. doi: 10.3892/mmr.2017.7104. Epub 2017 Jul 27. PMID: 28765972; PMCID: PMC5647098. 4. Goldhill J, Pichat P, Roome N, Angel I, Arbilla S. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung. 1998 Feb;48(2):179-84. PMID: 9541730.

In vitro protocol:

In vivo protocol:

1. Ren X, Zhang M, Chen L, Zhang W, Huang Y, Luo H, Li L, He H. The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model. Mol Med Rep. 2017 Oct;16(4):4045-4053. doi: 10.3892/mmr.2017.7104. Epub 2017 Jul 27. PMID: 28765972; PMCID: PMC5647098. 2. Goldhill J, Pichat P, Roome N, Angel I, Arbilla S. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung. 1998 Feb;48(2):179-84. PMID: 9541730.

1: Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. Review. PubMed PMID: 15312146. 2: Xia Q, Zhou WM, Yang S, Zhang SQ, Chen B, Wang DB, Wang Y, Zhang XJ. Influence of mizolastine on antigen-induced activation of signalling pathways in murine mast cells. Clin Exp Dermatol. 2006 Mar;31(2):260-5. PubMed PMID: 16487106. 3: Paśko P, Rodacki T, Domagała-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1 - antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother. 2017 Sep;93:27-39. doi: 10.1016/j.biopha.2017.06.008. Epub 2017 Jun 13. Review. PubMed PMID: 28622592. 4: Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology. 1996 Jun;34(2):101-4. PubMed PMID: 8876072. 5: Scadding GK, Tasman AJ, Murrieta-Aguttes M, Bachert C. Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis. Riperex Study Group. J Int Med Res. 1999;27(6):273-85. PubMed PMID: 10726236. 6: Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokinet. 2001;40(7):501-7. Review. PubMed PMID: 11510627. 7: Simons FE. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clin Exp Allergy. 1999 Mar;29 Suppl 1:3-8. Review. PubMed PMID: 10209699. 8: Grundmann JU, Böckelmann R, Bonnekoh B, Gollnick HP. UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin. Photochem Photobiol. 2001 Oct;74(4):587-92. PubMed PMID: 11683039. 9: Feng S, Nie L, Zou P, Suo J. Drug-loaded PLGA-mPEG microparticles as treatment for atopic dermatitis-like skin lesions in BALB/c mice model. J Microencapsul. 2015;32(2):201-9. doi: 10.3109/02652048.2014.995727. Epub 2014 Dec 24. PubMed PMID: 25539424. 10: Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol. 1999 Jan;12(1):16-24. PubMed PMID: 10188144. 11: Bachert C, Brostoff J, Scadding GK, Tasman J, Stalla-Bourdillon A, Murrieta M. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy. 1998 Oct;53(10):969-75. PubMed PMID: 9821477. 12: Patat A, Perault MC, Vandel B, Ulliac N, Zieleniuk I, Rosenzweig P. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):31-8. PubMed PMID: 7756096; PubMed Central PMCID: PMC1364978. 13: Triggiani M, Giannattasio G, Balestrieri B, Granata F, Gelb MH, de Paulis A, Marone G. Differential modulation of mediator release from human basophils and mast cells by mizolastine. Clin Exp Allergy. 2004 Feb;34(2):241-9. PubMed PMID: 14987304. 14: Delauche-Cavallier MC, Chaufour S, Guérault E, Lacroux A, Murrieta M, Wajman A. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. Clin Exp Allergy. 1999 Jul;29 Suppl 3:206-11. PubMed PMID: 10444239. 15: Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy. 1996 May;51(5):320-5. PubMed PMID: 8836336. 16: Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014 Nov 14;(11):CD006137. doi: 10.1002/14651858.CD006137.pub2. Review. PubMed PMID: 25397904. 17: Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol. 2000 Apr-May;10(3):205-11. PubMed PMID: 10725819. 18: Depoortere H, Decobert M, Granger P, Françon D. Mizolastine, a novel selective histamine H1 receptor antagonist: lack of sedative potential on the EEG in the rodent. Neuropsychobiology. 1995;32(4):214-21. PubMed PMID: 8587704. 19: Yan Y, Wang B, Zuo YG, Qu T. Inhibitory effects of mizolastine on ultraviolet B-induced leukotriene B4 production and 5-lipoxygenase expression in normal human dermal fibroblasts in vitro. Photochem Photobiol. 2006 May-Jun;82(3):665-9. PubMed PMID: 16402861. 20: Purohit A, Mélac M, Pauli G, Frossard N. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Clin Pharmacol. 2002 Mar;53(3):250-4. PubMed PMID: 11874388; PubMed Central PMCID: PMC1874315.